Benactyzine is an anticholinergic drug that was used as an antidepressant in the treatment of depression and associated anxiety before it was pulled from the U.S. market by the FDA due to its ineffectiveness.
Its use for these indications was limited by
side effects such as dry mouth and nausea, and at high doses it can cause more severe symptoms such as deliriant and hallucinogenic effects.
Brand names have included:
Suavitil, Phebex, Phobex, Cedad, Cevanol, Deprol, Lucidil, Morcain, Nutinal, Parasan. While there was some tentative evidence of effectiveness when combined with meprobamate, with the medication no longer available it is not clinically important.
History [ edit ]
Benactyzine was brought to market in the US in 1957 by
Merck under the tradename, Suavitil.
References [ edit ]
^ a b Shorter, E., Looking backwards: a possible new path for drug discovery in psychopharmacology. Nat Rev Drug Discov 2002, 1 (12), 1003–1006.
DeBattista, Alan F. Schatzberg, Jonathan O. Cole, Charles (2010). (7th ed.). Washington, DC: American Psychiatric Pub. p. 423. Manual of clinical psychopharmacology ISBN 978-1-58562-377-8.
^ Smith, Mickey C., PhD.
Principles of Pharmaceutical Marketing, Third Edition. 3rd ed. New York: Routledge, 2013. Print. ISBN 978-1-317-94071-5
External links [ edit ]